Holen Sie sich die Stockscreener-App
4.88
1.88%
0.09
Vorhandelsmarkt:
4.75
-0.13
-2.66%
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings - The Manila Times
First-in-Class Kidney Disease Drug XPHOZAH Reveals Breakthrough Clinical Results - Stock Titan
Commit To Purchase Ardelyx At $4, Earn 20.5% Annualized Using Options - Nasdaq
Institutional owners may take dramatic actions as Ardelyx, Inc.'s (NASDAQ:ARDX) recent 6.4% drop adds to one-year losses - simplywall.st
How to Take Advantage of moves in (ARDX) - news.stocktradersdaily.com
Shareholders that lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class ActionARDX - ACCESS Newswire
Ardelyx Requests to Dismiss Class Action Filed by Investors - TradingView
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - Marketscreener.com
ARDELYX INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Trading (ARDX) With Integrated Risk Controls - news.stocktradersdaily.com
Ardelyx honors inaugural Derek Forfang award winners By Investing.com - Investing.com Australia
Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth - Investing.com
Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth By Investing.com - Investing.com UK
Ardelyx honors inaugural Derek Forfang award winners - Investing.com India
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award - The Manila Times
Five Champions of Kidney Disease Advocacy Receive Groundbreaking Ardelyx Recognition - StockTitan
Insider Buying: David Mott Acquires Shares of Ardelyx Inc (ARDX) - GuruFocus.com
Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty By Investing.com - Investing.com South Africa
Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty - Investing.com India
8,020 Shares in Ardelyx, Inc. (NASDAQ:ARDX) Bought by SBI Securities Co. Ltd. - Defense World
Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities By Investing.com - Investing.com South Africa
Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities - Investing.com India
High Growth Tech Stocks In The US With Promising Potential - Simply Wall St
Ardelyx (NASDAQ:ARDX) Earns “Buy” Rating from LADENBURG THALM/SH SH - Defense World
Vistra, Ardelyx, Zscaler, Lexicon, Arista: Trending by Analysts - TipRanks
Ardelyx CEO Michael Raab sells $223,198 in stock - Investing.com
Scotiabank sets $15 target for Ardelyx stock, sees growth potential - Investing.com
Scotiabank sets $15 target for Ardelyx stock, sees growth potential By Investing.com - Investing.com South Africa
Ardelyx, Inc. to Host Earnings Call - ACCESS Newswire
Cantor Fitzgerald Predicts Ardelyx FY2025 Earnings - Defense World
Ardelyx (NASDAQ:ARDX) Raised to Strong-Buy at Cantor Fitzgerald - Defense World
Rhumbline Advisers Purchases 6,070 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
Ardelyx (NASDAQ:ARDX) Coverage Initiated by Analysts at BTIG Research - Defense World
BTIG sets Ardelyx stock Buy rating, $14 price target - Investing.com India
BTIG sets Ardelyx stock Buy rating, $14 price target By Investing.com - Investing.com South Africa
BTIG Initiates Ardelyx at Buy With $14 Price Target -March 04, 2025 at 07:10 am EST - Marketscreener.com
BTIG initiates Ardelyx with a Buy, sees attractive entry point after pullback - TipRanks
Class Action Filed Against Ardelyx, Inc. (ARDX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Ardelyx, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
Lost Money on Ardelyx, Inc.(ARDX)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
Reviewing Q32 Bio (NASDAQ:QTTB) & Ardelyx (NASDAQ:ARDX) - Defense World
Shareholders That Lost Money on Ardelyx, Inc. (ARDX) Should Contact Levi & Korsinsky About Pending Class ActionARDX - ACCESS Newswire
Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express + - Seeking Alpha
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - ACCESS Newswire
Los Angeles Capital Management LLC Has $2.38 Million Stock Position in Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
Ardelyx (NASDAQ:ARDX) Stock Price Up 5.3% on Insider Buying Activity - MarketBeat
ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Ardelyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024ARDX - ACCESS Newswire
Shareholders that lost money on Ardelyx, Inc. (ARDX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Insider Buying: Ardelyx, Inc. (NASDAQ:ARDX) Director Buys 77,729 Shares of Stock - MarketBeat
Wedbush Estimates Ardelyx's FY2029 Earnings (NASDAQ:ARDX) - MarketBeat
FINAL ARDX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ardelyx, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
HC Wainwright Estimates Ardelyx FY2029 Earnings - MarketBeat
Ardelyx (NasdaqGM:ARDX) Gets US$5M Milestone From China NDA Approval For Tenapanor In Dialysis Patients - simplywall.st
Shareholders that lost money on Ardelyx, Inc.(ARDX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Ardelyx director David Mott buys $388,738 in common stock By Investing.com - Investing.com South Africa
Ardelyx director David Mott buys $388,738 in common stock - Investing.com
2.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):